| HRA006643
(Controlled Access)
|
With immunotherapy-based combination (ICB) has been recommended as first-line treatment for advanced RCC, Labbate et al. initially reported a case of complete response of an extensive vena cava tumor thrombus with neoadjuvant immunotherapy. Though the safety and feasibility has been confirmed by following studies, the evidence was based on case report and series. Due to high objective response rate of ICB than TKI in advanced RCC, we hypothesized that the ICB would yield a higher reduction in level of inferior vena cave tumor thrombus (IVC-TT). This Phase 2 pilot study evaluated the efficacy and safety of neoadjuvant toripalimab plus axitinib for RCC with IVC-TT. |
